Search results
Results From The WOW.Com Content Network
Immunosuppression is a reduction of the activation or efficacy of the immune system. Some portions of the immune system itself have immunosuppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.
This file contains additional information, probably added from the digital camera or scanner used to create or digitize it. If the file has been modified from its original state, some details may not fully reflect the modified file.
Immunotherapy or biological therapy is the treatment of disease by activating or suppressing the immune system.Immunotherapy is designed to elicit or amplify an immune response are classified as activation immunotherapies, while immunotherapies that reduce or suppress are classified as suppression immunotherapies.
A common side-effect of many immunosuppressive drugs is immunodeficiency, because the majority of them act non-selectively, resulting in increased susceptibility to infections, decreased cancer immunosurveillance and decreased ability to produce antibodies after vaccination.
Due to the adverse risks associated with immunosuppressive drugs, it became apparent that the ideal strategy would be antigen-specific: a therapy that was able to inhibit the antigen-specific T-cell response, but would still leave the remainder of the immune system intact to defend against infection. [4]
A pair of federal government provisions designed to reduce excessive Social Security payouts are once again being targeted for elimination by U.S. lawmakers. At issue are the Windfall Elimination...
Under the HITECH Act, the United States Department of Health and Human Services (U.S. HHS) resolved to spend $25.9 billion to promote and expand the adoption of health information technology. [1] The Washington Post reported the inclusion of "as much as $36.5 billion in spending to create a nationwide network of electronic health records."
Days after FASTR was introduced in 2013, the Executive Branch's Office of Science and Technology Policy (OSTP) issued a memorandum that "hereby directs each Federal agency with over $100 million in annual conduct of research and development expenditures to develop a plan to support increased public access to the results of research funded by the Federal Government."